Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
Lakefront maintained its full-year 2026 cash guidance of approximately €2 billion, despite closing the €733.5 million acquisition of Ouro Medicines, and announced a new €50 million share repurchase program. The company reported H1 2026 revenue of €18.6 million, significantly lower than the prior year due to the completion of a large Gilead milestone, but swung to a net profit of €16.6 million driven by favorable financial investment valuations.
Key figures
- Eps
- 0.25
- Revenue
- 18600000
- Guidance
- Year-end 2026 cash and financial investments €1.975B-€2.050B; forecasts at least €1.6B remaining after funding portfolio to first gamgertamig approval
- Revenue Yoy
- -87%
- Buyback amount
- 50000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.